tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Consun Pharmaceutical Group Engages in Significant Wealth Management Subscriptions

Story Highlights
  • Consun’s subsidiaries subscribed to wealth management products totaling RMB875,500,000.
  • These transactions are discloseable under Hong Kong’s Listing Rules but don’t need shareholder approval.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Consun Pharmaceutical Group Engages in Significant Wealth Management Subscriptions

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Consun Pharmaceutical Group Ltd. ( (HK:1681) ) has shared an update.

Consun Pharmaceutical Group Ltd. has announced that its subsidiaries have subscribed to wealth management products from SPD Bank and its subsidiary, SPDB Wealth Management, with a total principal amount of RMB875,500,000. These transactions, funded by the company’s idle funds, are considered discloseable under Hong Kong’s Listing Rules due to their aggregated value exceeding certain percentage thresholds, though they do not require shareholder approval.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

More about Consun Pharmaceutical Group Ltd.

YTD Price Performance: 69.82%

Average Trading Volume: 2,553,556

Technical Sentiment Signal: Buy

Current Market Cap: HK$11.23B

Learn more about 1681 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1